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AbstrACt
background Patients with biliary tract cancer (BTC) 
have poor prognosis with few treatment options. 
Bintrafusp alfa, a first- in- class bifunctional fusion 
protein composed of the extracellular domain of the 
transforming growth factor (TGF)-βRII receptor (a 
TGF-β ‘trap’) fused to a human IgG1 antibody blocking 
programmed death ligand 1 (PD- L1), has shown clinical 
efficacy in multiple solid tumors.
Methods In this phase I, open- label trial expansion cohort, 
Asian patients with BTC whose disease progressed after 
first- line chemotherapy received bintrafusp alfa 1200 mg 
every 2 weeks until disease progression, unacceptable 
toxicity, or withdrawal. The primary endpoint is safety/
tolerability, while the secondary endpoints include best 
overall response per Response Evaluation Criteria in Solid 
Tumors version 1.1.
results As of August 24, 2018, 30 patients have 
received bintrafusp alfa for a median of 8.9 (IQR 
5.7–32.1) weeks; 3 patients remained on treatment 
for >59.7 weeks. Nineteen (63%) patients experienced 
treatment- related adverse events (TRAEs), most 
commonly rash (17%), maculopapular rash and fever 
(13% each), and increased lipase (10%). Eleven (37%) 
patients had grade ≥3 TRAEs; three patients had grade 5 
events (septic shock due to bacteremia, n=1; interstitial 
lung disease (reported term: interstitial pneumonitis), 
n=2). The objective response rate was 20% (95% CI 8 
to 39) per independent review committee (IRC), with 
five of six responses ongoing (12.5+ to 14.5+ months) 
at data cut- off. Two additional patients with durable 
stable disease had a partial response per investigator. 
Median progression- free survival assessed by IRC and 
overall survival were 2.5 months (95% CI 1.3 to 5.6) and 
12.7 months (95% CI 6.7 to 15.7), respectively. Clinical 
activity was observed irrespective of PD- L1 expression 
and microsatellite instability- high status.
Conclusions Bintrafusp alfa had clinical activity in Asian 
patients with pretreated BTC, with durable responses. 
Based on these results, bintrafusp alfa is under further 
investigation in patients with BTC (NCT03833661 and 
NCT04066491).
trial registration number NCT02699515.
bACkground
Biliary tract cancer (BTC) is a rare, lethal, 
heterogeneous gastrointestinal disease 
further subclassified into intrahepatic chol-
angiocarcinoma (IHCC), extrahepatic chol-
angiocarcinoma (EHCC), gallbladder cancer, 
and ampullary cancer.1 BTC causes 2.3 deaths 
per 100,000 population globally and is most 
common in Asia—in particular China, Japan, 
the Republic of Korea, and Thailand—
and Latin America, although its incidence 
varies geographically and depending on the 
subtype.1–3 Due to the initially asymptom-
atic nature of BTC, many patients present 
with locally advanced or metastatic disease at 
initial diagnosis and have poor prognosis.1 4
The current recommended first- line 
standard of care for unresectable, locally 
advanced, or metastatic disease is the combi-
nation of gemcitabine and cisplatin.4–6 There 
is currently no globally accepted standard- 
of- care treatment for locally advanced/
metastatic BTC for which standard chemo-
therapy has failed; however, the treatment 
landscape is evolving.7 8 According to a meta- 
analysis of second- line chemotherapy, objec-
tive response rates in prospective studies are 
<10% (with short response durations), and 
the median progression- free survival (mPFS) 
and overall survival (mOS) are <3 and <7 
months, respectively.7 The ABC-06 phase III 
trial in UK patients showed clinical benefit 
versus active symptom control, with mOS of 
6.2 months with oxaliplatin and 5- fluorouracil 
(mFOLFOX) vs 5.3 months with active 
symptom control.9 Preliminary results from 
the ClarIDHy phase III trial in patients with 
cholangiocarcinoma and mutations in the 
isocitrate dehydrogenase 1 (IDH1) gene 
showed ivosidenib versus placebo improved 
mPFS (2.7 vs 1.4 months) and OS (10.8 vs 
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Figure 1 Trial profile.
9.7 months), with 46% of patients reporting grade 3–4 
treatment- related adverse events (TRAEs).10 Despite posi-
tive outcomes with targeted agents,10–13 there remains an 
urgent unmet need in patients with BTC for which stan-
dard chemotherapy has failed.
One potential way to address this need is by focusing and 
enhancing the antitumor activity of the immune system.14 
Because tumor infiltration by certain cellular media-
tors of the adaptive immune system has been correlated 
with improved outcomes in BTC,15 immunotherapy has 
emerged as a promising treatment strategy. Indeed, high 
mutation rates in programmed death protein 1 (PD-1) and 
its ligand programmed death ligand 1 (PD- L1) have been 
observed,16 suggesting an important role of the PD- (L)1 
pathway in BTC pathogenesis. While the anti- PD-1 inhib-
itor, pembrolizumab, is approved in Japan for advanced, 
microsatellite instability- high (MSI- H) solid tumors that 
progressed on chemotherapy, there are limited clinical 
data available to assess the efficacy of immunotherapies in 
BTC and no indication- specific approvals.17–21
An additional mechanism shown to have a potentially 
important role in this cancer type is the transforming 
growth factor β (TGF-β) pathway. TGF-β signaling can 
promote tumor growth by exerting regulatory effects on 
both cancer cells and immune cells present in the tumor 
microenvironment (TME) and by inducing angiogen-
esis, fibrosis, and epithelial- mesenchymal transition, all 
of which are commonly associated with alterations of the 
TME and increased invasiveness in BTCs.22–24 Clinical data 
support the importance of TGF-β, as alterations within 
this pathway are frequently observed in BTC.25 26 There-
fore, removing TGF-β from the TME while simultaneously 
inhibiting the PD- (L)1 pathway—a non- redundant and 
complementary immunostimulatory mechanism—may 
provide a novel treatment approach in BTC.
Bintrafusp alfa (M7824) is a first- in- class bifunctional 
fusion protein composed of the extracellular domain 
of the human TGF-β receptor II (TGF-βRII or TGF-β 
‘trap’) fused via a flexible linker to the C- terminus of 
each heavy chain of an IgG1 antibody blocking PD- L1 
(anti- PD- L1). Data from two phase I trials of bintrafusp 
alfa (NCT02517398 and NCT02699515) have shown a 
manageable safety profile and encouraging early signs 
of clinical activity in patients with heavily pretreated 
advanced solid tumors.27–31 We report results from an 
expansion cohort of the phase I study designed to inves-
tigate the safety and efficacy of bintrafusp alfa in Asian 
patients with BTC unselected for PD- L1 expression and 
for which standard chemotherapy has failed.
Methods
study design and participants
This report describes an expansion cohort of a phase I, 
open- label trial of bintrafusp alfa in Asian (Japan, Korea, 
Taiwan) patients with metastatic or locally advanced solid 
tumors. Eligible patients had histologically or cytologically 
confirmed BTC, with at least one lesion measurable by 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1, in patients who had failed prior chemo-
therapy (including in the neoadjuvant or adjuvant 
setting). Patients were aged 20 years or older; had a life 
expectancy of at least 12 weeks; an Eastern Cooperative 
Oncology Group performance status ≤1; and adequate 
hepatic, renal, and hematological function. In addition, 
the availability of tumor (primary or metastatic) archival 
material or fresh biopsies within 28 days before the first 
administration of bintrafusp alfa was mandatory. Patient 
selection was not based on tumor expression of PD- L1 
or other biomarkers. Exclusion criteria included prior 
therapy with inhibitors of T cell coregulatory proteins or 
with any antibody/drug targeting TGF-β/TGF-β receptor, 
significant acute or chronic infections, an active auto-
immune disease, and rapidly progressive disease (PD; 
which, in the opinion of the investigator, may predispose 
to inability to tolerate treatment or trial procedures). Full 
details on exclusion/inclusion criteria are available in the 
online supplementary information.
Each patient provided written informed consent before 
study enrollment.
Procedures
Bintrafusp alfa was administered at 1200 mg via intra-
venous infusion over 1 hour once every 2 weeks until 
confirmed PD, unacceptable toxicity, or trial withdrawal. 
Dosing modifications, such as changes in infusion rate, 
and dose delays were allowed; however, dose reductions 
were not permitted. To mitigate potential infusion- related 
reactions, premedication with an antihistamine and acet-
aminophen 30–60 min prior to each dose of bintrafusp 
alfa was mandatory. Steroids as premedication were 
not allowed. PD- L1 immunohistochemistry (IHC) was 
performed by using antibody clone 73-10 (Dako PD- L1 
IHC 73-10 pharmDx; Dako, Carpinteria, California, 
USA) on fresh or archival tissue; tumors were categorized 
based on the proportion of tumor cells expressing PD- L1 
according to a threshold of 1% as positive (≥1%) or nega-
tive (<1%). To assess the correlation between specific 
TGF-β-related or immune- related biomarkers and patient 
response to bintrafusp alfa treatment, gene expression 
analysis was done on pretreatment tumor samples. Full 
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Table 1 Baseline patient and disease characteristics
N=30
Sex
  Male 19 (63)
  Female 11 (37)
Age, years
  Median (IQR) 67 (58–69)
ECOG performance status
  0 8 (27)
  1 22 (73)
Biliary tract cancer classification
  Gallbladder cancer 12 (40)
  Intrahepatic cholangiocarcinoma 10 (33)
  Extrahepatic cholangiocarcinoma 7 (23)
  Ampullary cancer 1 (3)
Number of prior anticancer therapies*
  1 26 (87)
  2 3 (10)
  3 1 (3)
PD- L1 expression†
  Positive 16 (53)
  Negative 13 (43)
  Not evaluable 1 (3)
HBV/HCV positivity
  HBsAg 1 (3)
  HBsAb 8 (27)
  HBcAb 13 (43)
  HBV- DNA 0
  HCV Ab 0
Immune phenotype status
  Immune- desert 3 (10)
  Immune- excluded 23 (77)
  Inflamed 2 (7)
  Not evaluable 2 (7)
Data are n (%) unless otherwise specified.
Positive: PD- L1 expression in ≥1% of tumor cells; negative: PD- L1 
expression in <1% of tumor cells.
*Include neoadjuvant and adjuvant therapies.
†Defined as the proportion of tumor cells showing membranous PD- L1 
staining.
HCV Ab, antibody [NOTE: THIS IS PUTTING HCV Ab IN PROOF. 
SHOULD BE: "Ab, antibody"]; ECOG, Eastern Cooperative Oncology 
Group; HBcAb, hepatitis B virus core antibody; HBsAb, hepatitis B 
virus surface antibody; HBsAg, hepatitis B virus surface antigen; HBV, 
hepatitis B virus; HBV- DNA, hepatitis B virus DNA; HCV, hepatitis C 
virus; PD- L1, programmed death ligand 1.
Table 2 Treatment- related adverse events occurring in 
≥5% of patients or of grade 3–4 severity
N=30
Any grade Grade 3–4
Any treatment- related adverse event 19 (63) 11 (37)
  Rash 5 (17) 4 (13)
  Fever 4 (13) 0
  Maculopapular rash 4 (13) 0
  Lipase increased 3 (10) 3 (10)
  Anemia 2 (7) 1 (3)
  Fatigue 2 (7) 0
  Hypothyroidism 2 (7) 0
  Alanine aminotransferase increased 2 (7) 1 (3)
  Amylase increased 2 (7) 2 (7)
  Aspartate aminotransferase 
increased
2 (7) 1 (3)
  Blood alkaline phosphatase 
increased
2 (7) 0
  Gamma- glutamyltransferase 
increased
2 (7) 2 (7)
  Infusion- related reaction 2 (7) 0
  Eczema 1 (3) 1 (3)
  Lichenoid dermatitis 1 (3) 1 (3)
  Lip squamous cell carcinoma 1 (3) 1 (3)
  Seborrheic keratosis 1 (3) 1 (3)
Skin lesions* 2 (7) 0
  Keratoacanthoma 2 (7) 0
Data are n (%).
*Include MedDRA V.21.0 preferred terms squamous cell 
carcinoma of the skin, basal cell carcinoma, keratoacanthoma, 
hyperkeratosis, and actinic keratosis.
details on biomarker analyses can be found in the online 
supplementary information.
outcomes
The primary endpoints of this trial are the number, 
severity, and duration of TRAEs according to National 
Cancer Institute Common Terminology Criteria for 
Adverse (NCI-CTCAE) version 4.03. Safety was assessed 
and documented at every visit, which included moni-
toring for adverse events, evaluation of performance 
status, physical examination, and clinical laboratory 
tests. Immune- related adverse events (irAEs) were iden-
tified using a list of preselected Medical Dictionary for 
Regulatory Activities (MedDRA) terms and must have 
begun after the first administration of bintrafusp alfa 
and no more than 90 days after the last treatment dose. 
Also, irAEs must have been treated with corticosteroids, 
immunosuppressants, or hormonal therapy and have no 
clear etiology. Secondary endpoints of this expansion 
cohort include best overall response (BOR) per inde-
pendent review committee (IRC) and investigator assess-
ment, duration of response, disease control rate, PFS per 
IRC assessment, and OS. The results described in this 
report include efficacy as assessed by the investigator and 
IRC. Tumor response was evaluated by CT or MRI and 
confirmed by repeated imaging assessment ≥4 weeks from 
the first documentation of response. Assessments were 
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Figure 2 Change in target lesions from baseline as adjudicated by the IRC. Responses were assessed in accordance with 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The upper dotted line represents progression at 20% 
increase in size of target lesions, and the lower dotted line represents the RECIST boundary for complete response or partial 
response at 30% decrease in size of target lesions. Patients with no postbaseline assessment (n=2) or no target lesions 
identified by the IRC before first dose (n=2) are not displayed. *Patients with MSI- H phenotype. †MSI phenotype not available 
due to no leftover sample. ‡Patients with unavailable tumor mutation count data. §Patient with poststudy tumor shrinkage of 
non- target lesions. ‖Patients with an investigator- assessed best overall response of partial response. #Patient with a partial 
response following pseudoprogression per investigator assessment (best overall response per investigator, progressive 
disease). CR, complete response; MSI- H, microsatellite instability- high; PR, partial response.
performed every 6 weeks during the treatment period, 
then every 12 weeks.
statistical analysis
Analysis of safety and efficacy was performed in all patients 
who received at least one dose of bintrafusp alfa. Along 
with proportions of patients with objective responses, 
corresponding exact two- sided 95% CIs were calculated 
using the Clopper- Pearson method. Duration of tumor 
response, PFS, and OS were analyzed using the Kaplan- 
Meier method.
results
From February 1, 2017 to May 30, 2017, 30 Asian patients 
with pretreated BTC were enrolled (figure 1). The median 
age was 67 (IQR 58–69) years, and most (n=19, 63%) were 
male (table 1). In terms of disease site, 12 (40%) patients 
had gallbladder cancer, 10 (33%) had IHCC, 7 (23%) 
had EHCC, and 1 (3%) had ampullary cancer. Sixteen 
(53%) patients had positive PD- L1 expression, as defined 
by ≥1% tumor cell PD- L1 expression. At first diagnosis, 12 
(40%) patients presented with distant metastatic disease. 
All 30 patients had received prior anticancer therapy, 
including platinum- based therapies in 25 (83%) patients.
As of the database cut- off (August 24, 2018), the median 
Kaplan- Meier estimate of follow- up was 15.3 months. 
The median duration of therapy was 8.9 (IQR 5.7–32.1) 
weeks, and three patients remained on active treatment 
(for >59.7 weeks). In the 27 patients who discontinued 
treatment with bintrafusp alfa, the most common reason 
was PD (n=17).
Among the 30 patients who received bintrafusp alfa, the 
most common TRAEs occurring at any grade were rash 
(17%), fever and maculopapular rash (13% each), and 
lipase increased (10%) (table 2). Eleven (37%) patients 
experienced grade ≥3 TRAEs; six patients experienced 
at least one TRAE of maximum grade 3, and TRAEs of 
maximum grade 4 occurred in two patients (amylase 
increased and lipase increased; amylase increased, aspar-
tate aminotransferase increased, and lipase increased).
Three patients died due to toxicities. The first patient 
was from Taiwan and had a medical history of ichthyosis 
vulgaris; the patient developed symptoms of an infection 
before an emergency room visit and had taken amoxi-
cillin/clavulanic acid without a physician visit, in addition 
to receiving local and systemic steroids for treatment- 
related lichenoid dermatitis over 4 months. Subse-
quently, the patient suffered from septic shock, which 
was attributed by the investigator to Staphylococcus aureus 
bacteremia, a secondary infection of an underlying skin 
condition, which ultimately led to death on day 249 (14 
days after the last dose of bintrafusp alfa). The second 
patient was from Japan and had grade 3 interstitial lung 
disease (ILD; reported term: interstitial pneumonitis) 
after three doses of bintrafusp alfa, which improved to 
grade 1 on treatment with prednisolone, but ultimately led 
to discontinuation of bintrafusp alfa. The patient subse-
quently initiated chemotherapy due to PD, and 6 months 
after initial ILD diagnosis and 6 months and 4 days after 
last bintrafusp alfa administration, the ILD intensified 
to grade 4 and led to death. The third patient was from 
Japan and was hospitalized for grade 2 nausea, vomiting, 
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Figure 3 Time to and duration of response as adjudicated by the IRC. Responses were assessed in accordance with 
Response Evaluation Criteria in Solid Tumors version 1.1.






  Complete response 1 (3) 2 (7)
  Partial response 6 (20) 4 (13)
  Stable disease 4 (13) 6 (20)
  Progressive disease 17 (57) 16 (53)
  Not evaluable 2 (7) 2 (7)
Objective response rate 7 (23%, 95% CI 10 to 42) 6 (20%, 95% CI 8 to 39)
Objective response by biliary tract cancer subtype
  Ampullary cancer 0/1 (0) 0/1 (0)
  Extrahepatic cholangiocarcinoma 1/7 (14) 0/7 (0)
  Gallbladder cancer 2/12 (17)* 3/12 (25)
  Intrahepatic cholangiocarcinoma 4/10 (40%) 3/10 (30%)
Disease control rate 11 (37%, 95% CI 20 to 56) 12 (40%, 95% CI 23 to 59)
Median duration of response (range), months 9.7 (2.8–12.5) NE (8.3–14.5)
Median progression- free survival (95% CI), months 2.5 (1.3 to 4.0) 2.5 (1.3 to 5.6)
Median overall survival (95% CI), months 12.7 (6.7 to 15.7)
Data are n (%) unless otherwise specified.
Responses were assessed in accordance with Response Evaluation Criteria in Solid Tumors version 1.1.
Only confirmed responses are included.
*One patient with gallbladder cancer had a partial response per IRC and initial pseudoprogression on the first evaluation visit, followed by a 
partial response as assessed by the investigator (investigator- assessed best overall response, progressive disease).
NE, not evaluable.
and appetite loss on day 33. Grade 3 ILD (reported 
term: interstitial pneumonitis) developed in hospital on 
day 45—after three doses of bintrafusp alfa and 17 days 
after the last dose—which intensified to grade 4 after 3 
days despite treatment with prednisolone, tazobactam- 
piperacillin, and sulfamethoxazole- trimethoprim, and 
ultimately led to death. Information on the results of an 
infectious blood panel was not provided by the hospital.
Treatment discontinuation due to a TRAE was observed 
in six patients (anemia (n=1), ILD (n=1; described above), 
alanine aminotransferase increased and aspartate amino-
transferase increased (n=1), amylase increased and lipase 
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Figure 4 Kaplan- Meier analysis of progression- free survival as adjudicated by the IRC (A) and overall survival (B).
increased (n=1), gamma- glutamyltransferase increased 
(n=1), and septic shock (n=1; described above)). Macu-
lopapular rash (n=4) was the only irAE that occurred in 
>2 patients (online supplementary table S1). No grade 
≥3 infusion- related adverse events were observed. Two 
patients had potentially TGF-β-mediated skin lesions 
(keratoacanthoma).
Objective responses were confirmed in six patients as 
adjudicated by the IRC, for an objective response rate 
of 20% (95% CI 8 to 39) according to RECIST version 
1.1 (figure 2, table 3). Two patients had a complete 
response (CR), each with a response duration of 12.5+ 
months. Among the four patients with a partial response 
(PR), three had a response that was ongoing at the time 
of database cut- off, with response durations of 13.8+, 
13.9+, and 14.5+ months. The fourth patient with a PR 
had a response duration of 8.3 months per IRC, which 
was considered ongoing as of the last assessment, and an 
investigator- assessed duration of response of 9.7 months 
before disease progression (figure 3). One of the patients 
with a PR per IRC and BTC subtype of gallbladder cancer 
had, as assessed by the investigator, initial pseudoprogres-
sion on the first evaluation visit, followed by a PR that 
was ongoing for 14.5+ months and tumor regression of 
65% from baseline as of the cut- off date. At the time of 
this writing, this patient’s response was near CR and was 
ongoing (26+ months). Six patients had a BOR of stable 
disease per IRC, for a disease control rate of 40%. In addi-
tion to the six patients with a confirmed response per IRC, 
two patients with a BOR of stable disease per IRC (time to 
progression, 6.9 and 8.2 months) had a confirmed PR for 
2.8 and 5.6 months per investigator (investigator- assessed 
objective response rate, 23%; table 3, online supplemen-
tary figure S1), and one patient with ampullary cancer had 
shrinkage of lung and liver non- target lesions after having 
stopped study treatment and receiving radiotherapy 
(Gamma Knife radiosurgery; Elekta, Stockholm, Sweden) 
for a brain lesion, for a total clinical response rate (objec-
tive response rate + delayed response after initial progres-
sion) of 30% (9 of 30) (figure 2, online supplementary 
figure S1). The mPFS was 2.5 months (95% CI 1.3 to 5.6), 
with 6- month and 12- month PFS rates of 32% and 24%, 
respectively. Furthermore, an mOS of 12.7 months (95% 
CI 6.7 to 15.7) and 6- month and 12- month OS rates of 
73% and 52%, respectively, were observed (figure 4).
The objective response rates by BTC subtype were 30% 
and 25% in patients with IHCC and gallbladder cancer, 
respectively, as adjudicated by IRC. Complete responses 
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were recorded in one patient with gallbladder cancer 
and one patient with IHCC; no objective response was 
recorded in patients with ampullary cancer or EHCC. 
Of the two additional patients with a confirmed PR per 
investigator assessment (described above), one patient 
had IHCC and one had EHCC (figure 2).
Among patients with PD- L1- positive (expression on 
≥1% of tumor cells) and PD- L1- negative tumors, the 
confirmed objective response rates per IRC were 19% 
and 23%, respectively (online supplementary figure S2). 
Responses were observed across the range of expression 
levels of various biomarkers relevant to the mechanism 
of action of bintrafusp alfa, including markers of CD8+ 
T cells, cytokines (IFNG and TGFB1), and mesenchymal 
markers (VIM and TWIST1) (online supplementary figure 
S3A- F). Similarly, there was no apparent correlation 
between response and tumor mutation count (figure 2). 
Two patients were identified as having MSI- H status, 
with one patient having stable disease and one patient 
achieving a CR (figure 2). Furthermore, immune pheno-
type was evaluable in tumor samples from 28 patients, and 
responses were observed in patients with immune- desert 
tumors (one PR; defined as <1% of the tumor stroma area 
populated by lymphocytes, no dense immune cell infil-
trates, and no contact of immune cells with tumor cells) 
and in those with immune- excluded tumors (three PRs 
and two CRs; defined as ≥1% of the tumor stroma area 
populated by lymphocytes, immune cells possibly located 
in the immediate vicinity of tumor cells but not efficiently 
infiltrate tumor cell clusters, and very infrequent physical 
contact between lymphocytes and tumor cells) (online 
supplementary figure S3G).
disCussion
Bintrafusp alfa demonstrated clinical activity in this cohort 
of Asian patients with BTC whose disease has progressed 
with standard chemotherapy, consistent with findings 
from the dose- escalation phase28 30 and other expansion 
cohorts of the present trial27 and the global, phase I study 
(NCT02517398).29 31 Indeed, the objective response rate 
was 20% per independent read, with durable responses 
observed. Additionally, the response rate per investi-
gator was 23%, and the total clinical response (objective 
response rate + delayed response after initial progres-
sion) was 30%. Furthermore, second- line treatment with 
bintrafusp alfa showed an mOS of 12.7 months in the 
overall population. These efficacy results compare favor-
ably with historical data in pretreated patients receiving 
second- line or later treatment, where most chemotherapy 
regimens have an mOS <1 year,7 as well as with results 
observed with immune cell inhibitor monotherapy in a 
Japanese phase I study of nivolumab (JapicCTI-153098), 
a phase II study of pembrolizumab (NCT02628067), and 
the phase III study (NCT01926236) of mFOLFOX (objec-
tive response rates of 3%, 6%, and 5%, respectively).9 18 19
Clinical activity was observed across BTC subtypes and 
irrespective of PD- L1 expression on tumor cells or in the 
TME (data not shown). Previous studies have suggested 
a link between response to anti- PD- L1 therapy and 
immune phenotype.32 However, responses observed in 
this study were recorded in patients with immune- desert 
and immune- excluded phenotypes, with most (five of six) 
occurring in the latter. Additionally, no correlation was 
observed between response and tumor mutation count, a 
surrogate for tumor mutational burden. Finally, only one 
of the six responders had an MSI- H phenotype. Overall, 
the lack of a discrete, single biomarker associated with 
response to bintrafusp alfa in this small cohort of patients 
underscores the value of dual inhibition of both the 
TGF-β and PD- L1 pathways as a promising therapeutic 
option for patients with locally advanced/metastatic BTC.
Incidence, severity and type of irAEs observed with 
bintrafusp alfa were comparable with those seen with 
immune checkpoint inhibitors.33 In addition to one 
septic shock event due to bacteremia that led to death, 
two ILD (interstitial pneumonitis) events led to death in 
this cohort, one of which occurred 6 months after the 
last bintrafusp alfa dose, which was followed by chemo-
therapy treatment and PD. Both were the only ILD 
events resulting in death observed in the entire phase I 
bintrafusp alfa program. Across both phase I trials investi-
gating bintrafusp alfa (NCT02699515 and NCT02517398; 
combined N=689 as of August 24, 2019), the overall inci-
dence of ILD occurring at any grade, grade ≥3, and grade 
5 was 3%, 1%, and <1%, respectively. Furthermore, the 
occurrence of ILD in Japanese patients reported in this 
study is consistent with the higher incidence of drug- 
induced ILD among Japanese patients than that observed 
among the non- Japanese populations in other studies. 
Although the incidence of drug- induced ILD has alarm-
ingly increased over the past decade in Japan, little is 
known about its cause, and no specific risk factors for ILD 
have been determined to date.34 Ongoing phase II/III 
trials of bintrafusp alfa will offer greater insights into the 
full safety and efficacy profile of bintrafusp alfa, as well as 
evaluate potential predictive biomarkers.
This study has certain limitations. The lack of a compar-
ator group and the small number of patients enrolled in 
this study preclude any direct comparison between bintra-
fusp alfa and available therapies for this patient popu-
lation. Additionally, the lack of non- Asian patients may 
represent a further limitation of this study. Nevertheless, 
this cohort highlights the efficacy of a novel anticancer 
agent in patients from a region with a high incidence of 
BTC.
ConClusions
Given the biological link between BTC and both TGF-β 
and PD- (L)1 signaling,16 25 26 35 36 the concomitant inhibi-
tion of these two non- redundant, protumorigenic, immu-
nosuppressive pathways with bintrafusp alfa may provide 
enhanced clinical benefit and thus represents a potential 
therapy for BTC. Indeed, in this study of Asian patients 
with heavily pretreated BTC who had limited treatment 
8 Yoo C, et al. J Immunother Cancer 2020;8:e000564. doi:10.1136/jitc-2020-000564
Open access 
options, bintrafusp alfa demonstrated promising early 
signs of clinical activity irrespective of PD- L1 expression, 
tumor mutation count, MSI- H status, and primary tumor 
location, with an objective response rate of 20% per IRC, 
overall antitumor activity in 30% of patients (including 
two patients with a PR as assessed by the investigator and 
one patient with poststudy tumor shrinkage of non- target 
lesions), and mOS of 12.7 months. Based on these find-
ings, further study of bintrafusp alfa treatment in patients 
with BTC is warranted, and is ongoing in a phase II trial 
as monotherapy in second- line BTC (NCT03833661) and 
a phase II/III trial in combination with gemcitabine and 
cisplatin (NCT04066491).
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